Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazonium Sulfate for Invasive Mold Infections in Chinese Adults
CTR20222787Phase 4Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of isavuconazole in invasive aspergillosis (IA), mucormycosis and invasive mycoses, sponsored by Basilea Pharmaceutica. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs) by system organ class (SOC) and preferred term (PT). Started Nov 2022; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)mucormycosisinvasive mycoses
Beyond the preview
Go deeper on CTR20222787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222787.